EyeGate Pharmaceuticals, a US-based medical device and treatment provider for dry eyes, has extended its series D round to $28.5m.
A regulatory filing said nine investors provided $4.5m and said Paul Chaney from OSI Pharmaceuticals is a director. However, the company said it had gained $5.9m as part of its series D closing and raised a total of $28.5m in the round.
In January last year, EyeGate raised $22.6m in the initial closing of its D round from venture capital firms Ventech, Innoven Partners, Medicis Capital, Natixis Private Equity and Emerging Capital.
EyeGate raised $15m in its series C round in March 2008, $12m the year before.